Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome

Transplantation

Volumn 74, Issue 8, 2002, Pages 1095-1102

  Dotti, Gianpietro ^a   Fiocchi, Roberto ^a   Motta, Teresio ^a   Mammana, Carmelo ^a   Gotti, Eliana ^a   Riva, Silvia ^a   Cornelli, Pieremilio ^a   Gridelli, Bruno ^a   Viero, Piera ^a   Oldani, Elena ^a   Ferrazzi, Paolo ^a   Remuzzi, Giuseppe ^a   Barbui, Tiziano ^a   Rambaldi, Alessandro ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAUNORUBICIN DERIVATIVE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; OKT 3; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LIVER TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037184327     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00007     Document Type: Article

References (43)

1. Penn I. The changing pattern of posttransplant malignancies. Transplantation Proc 1991; 23: 1101.
2. Hanto DW, Frizzera C, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4253.
3. Lebland M, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998; 16: 2052.
4. Dotti G, Fiocchi R, Motta T, et al. EBV-negative lymphoproliferative disorders in long term survivors after heart, kidney and liver transplant. Transplantation 2000; 69: 827.
5. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein Barr Virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375.
6. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991; 70: 137.
7. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552.
8. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
9. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
10. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82: 1978.
11. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076.
12. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998; 20: 343.
13. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770.
14. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137.
15. Milpied N, Vasseur B, Parquet N, et al. Humanized anti CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorders: A retrospective analysis on 32 patients. Ann Oncol 2000; 11(suppl 1): S113.
16. Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86: 618.
17. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patient: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
18. Garret TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72: 2782.
19. Swinnen LJ, Mullen GM, Carr JT, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
20. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961.
21. Spada M, Corno V, Colledan M, et al. Rejection and tacrolimus conversion therapy in paediatric liver transplantation. Transpl Int 2000; (suppl 1) 13: S341.
22. Frizzera G, Hanto DW, Gail-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
23. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: From the past to the present. Semin Diagn Pathol 1997; 14: 2.
24. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835.
25. Barbui T, Rambaldi A, Parenzan L, et al. Neurologic symptoms and come associated with doxorubicin administration during chronic cyclosporine therapy. Lancet 1992; 339: 1421.
26. Cortelazzo S, Rossi A, Viero P, et al. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 1997; 99: 379.
27. Martelli M, Guglielmi C, Coluzzi S, et al. P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2362.
28. Bassan R, Battista R, Corneo G, et al. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: The effect of drug schedule on outcome. Leuk Lymphoma 1993; 11: 105.
29. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353.
30. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649.
31. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630.
32. Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplant: A new entity associated with human herpesvirus-8. Leukemia 1999; 13: 664.
33. Duhmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19: 2905.
34. Kaminski MS, Coleman CN, Colby TV, et al. Factors predicting survival in adults with stage I and stage II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 19865; 104: 747.
35. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 367.
36. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772.
37. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622.
38. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001; 23: 14.
39. Gallego-Melcon S, Sanchez de Toledo J, Martinez V, et al. Non-Hodgkin's lymphoma after liver transplantation: Response to chemotherapy. Med Pediatr Oncol 1996; 27: 156.
40. Smets F, Vajro P, Cornu G, et al. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000; 27: 1015.
41. Leung W, Colombani P, Lau H, et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. Transplantation 1999; 67: 1487.
42. Chiodini B, Bassan R, Barbui T. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Leuk Lymphoma 1999; 33: 485.
43. Haddad E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorders with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase I-II clinical trial. Blood 2001; 97: 1590.